Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Colorectal Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 30 articles: HTML format Text format

Single Articles

October 2019
1. MODEST DP, Martens UM, Riera-Knorrenschild J, Greeve J, et al
   FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
   J Clin Oncol. 2019 Oct 14:JCO1901340. doi: 10.1200/JCO.19.01340.
   PubMed     Text format     Abstract available
   
   
   September 2019
2. SUNDAR R, Tan IBH, Chee CE
   Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead.
   J Clin Oncol. 2019 Sep 24:JCO1901977. doi: 10.1200/JCO.19.01977.
   PubMed     Text format    
   
   
   
3. MORANO F, Corallo S, Lonardi S, Raimondi A, et al
   Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
   J Clin Oncol. 2019 Sep 20:JCO1901254. doi: 10.1200/JCO.19.01254.
   PubMed     Text format     Abstract available
   
   
   August 2019
4. GUERCIO BJ, Zhang S, Ou FS, Venook AP, et al
   Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
   J Clin Oncol. 2019 Aug 13:JCO1901019. doi: 10.1200/JCO.19.01019.
   PubMed     Text format     Abstract available
   
   
   June 2019
5. UENO H, Ishiguro M, Nakatani E, Ishikawa T, et al
   Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
   J Clin Oncol. 2019 Jun 10:JCO1802059. doi: 10.1200/JCO.18.02059.
   PubMed     Text format     Abstract available
   
   
   
6. STEBBING J, Singh Wasan H
   Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making.
   J Clin Oncol. 2019 Jun 7:JCO1901185. doi: 10.1200/JCO.19.01185.
   PubMed     Text format    
   
   
   May 2019
7. SMITH TG, Troeschel AN, Castro KM, Arora NK, et al
   Perceptions of Patients With Breast and Colon Cancer of the Management of Cancer-Related Pain, Fatigue, and Emotional Distress in Community Oncology.
   J Clin Oncol. 2019 May 17:JCO1801579. doi: 10.1200/JCO.18.01579.
   PubMed     Text format     Abstract available
   
   
   
8. LENZ HJ, Ou FS, Venook AP, Hochster HS, et al
   Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
   J Clin Oncol. 2019 May 1:JCO1802258. doi: 10.1200/JCO.18.02258.
   PubMed     Text format     Abstract available
   
   
   April 2019
9. LIEU C, Kennedy EB, Bergsland E, Berlin J, et al
   Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
   J Clin Oncol. 2019 Apr 15:JCO1900281. doi: 10.1200/JCO.19.00281.
   PubMed     Text format     Abstract available
   
   
   March 2019
10. VAN CUTSEM E, Huijberts S, Grothey A, Yaeger R, et al
    Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
    J Clin Oncol. 2019 Mar 20:JCO1802459. doi: 10.1200/JCO.18.02459.
    PubMed     Text format     Abstract available
    
    
    
11. INNOCENTI F, Ou FS, Qu X, Zemla TJ, et al
    Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
    J Clin Oncol. 2019 Mar 13:JCO1801798. doi: 10.1200/JCO.18.01798.
    PubMed     Text format     Abstract available
    
    
    January 2019
12. OGURA A, Konishi T, Cunningham C, Garcia-Aguilar J, et al
    Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.
    J Clin Oncol. 2019;37:33-43.
    PubMed     Text format     Abstract available
    
    
    November 2018
13. MODEST DP, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, et al
    Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
    J Clin Oncol. 2018 Nov 2:JCO1800052. doi: 10.1200/JCO.18.00052.
    PubMed     Text format     Abstract available
    
    
    October 2018
14. GUINTER MA, McCullough ML, Gapstur SM, Campbell PT, et al
    Associations of Pre- and Postdiagnosis Diet Quality With Risk of Mortality Among Men and Women With Colorectal Cancer.
    J Clin Oncol. 2018 Oct 19:JCO1800714. doi: 10.1200/JCO.18.00714.
    PubMed     Text format     Abstract available
    
    
    September 2018
15. QIN S, Li J, Wang L, Xu J, et al
    Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.
    J Clin Oncol. 2018 Sep 10:JCO2018783183. doi: 10.1200/JCO.2018.78.3183.
    PubMed     Text format     Abstract available
    
    
    June 2018
16. MO M, Yang J, Zhu X, Zhu J, et al
    Bevacizumab Maintenance in Metastatic Colorectal Cancer.
    J Clin Oncol. 2018 Jun 4:JCO2018783795. doi: 10.1200/JCO.2018.78.3795.
    PubMed     Text format    
    
    
    May 2018
17. VAN DIJK E, Biesma HD, Cordes M, Smeets D, et al
    Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
    J Clin Oncol. 2018 May 24:JCO2017771782. doi: 10.1200/JCO.2017.77.1782.
    PubMed     Text format     Abstract available
    
    
    April 2018
18. VENOOK AP
    Advances in Adjuvant Therapy for Colon Cancer: P value or Practical Value.
    J Clin Oncol. 2018 Apr 5:JCO2018778423. doi: 10.1200/JCO.2018.77.8423.
    PubMed     Text format    
    
    
    
19. ANDRE T, Vernerey D, Mineur L, Bennouna J, et al
    3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    J Clin Oncol. 2018 Apr 5:JCO2017760355. doi: 10.1200/JCO.2017.76.0355.
    PubMed     Text format     Abstract available
    
    
    
20. SOBRERO A, Lonardi S, Rosati G, Di Bartolomeo M, et al
    FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    J Clin Oncol. 2018 Apr 5:JCO2017762187. doi: 10.1200/JCO.2017.76.2187.
    PubMed     Text format     Abstract available
    
    
    March 2018
21. SUN R, Horiguchi M, Wei LJ
    Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival.
    J Clin Oncol. 2018 Mar 20:JCO2017775643. doi: 10.1200/JCO.2017.77.5643.
    PubMed     Text format    
    
    
    February 2018
22. FADELU T, Zhang S, Niedzwiecki D, Ye X, et al
    Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
    J Clin Oncol. 2018 Feb 28:JCO2017755413. doi: 10.1200/JCO.2017.75.5413.
    PubMed     Text format     Abstract available
    
    
    January 2018
23. OVERMAN MJ, Lonardi S, Wong KYM, Lenz HJ, et al
    Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
    J Clin Oncol. 2018 Jan 20:JCO2017769901. doi: 10.1200/JCO.2017.76.9901.
    PubMed     Text format     Abstract available
    
    
    
24. APARICIO T, Ghiringhelli F, Boige V, Le Malicot K, et al
    Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).
    J Clin Oncol. 2018 Jan 18:JCO2017752931. doi: 10.1200/JCO.2017.75.2931.
    PubMed     Text format     Abstract available
    
    
    
25. KENZIK KM, Balentine C, Richman J, Kilgore M, et al
    New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer.
    J Clin Oncol. 2018 Jan 16:JCO2017749739. doi: 10.1200/JCO.2017.74.9739.
    PubMed     Text format     Abstract available
    
    
    December 2017
26. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    PubMed     Text format     Abstract available
    
    
    
27. XU J, Kim TW, Shen L, Sriuranpong V, et al
    Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
    J Clin Oncol. 2017 Dec 7:JCO2017743245. doi: 10.1200/JCO.2017.74.3245.
    PubMed     Text format     Abstract available
    
    
    November 2017
28. COLON-LOPEZ V, Shiels MS, Machin M, Ortiz AP, et al
    Anal Cancer Risk Among People With HIV Infection in the United States.
    J Clin Oncol. 2017 Nov 15:JCO2017749291. doi: 10.1200/JCO.2017.74.9291.
    PubMed     Text format     Abstract available
    
    
    
29. WHITNEY RL, Bell JF, Tancredi DJ, Romano PS, et al
    Hospitalization Rates and Predictors of Rehospitalization Among Individuals With Advanced Cancer in the Year After Diagnosis.
    J Clin Oncol. 2017;35:3610-3617.
    PubMed     Text format     Abstract available
    
    
    February 2017
30. LOBERG M, Holme O, Kalager M
    Aspirin, Colorectal Cancer, and Cause of Death: A Complex Landscape.
    J Clin Oncol. 2017;35:568-569.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: